Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Michigan Prior Auth Polic…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    Prior authorization and step therapy criteria for formulary drugs

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists medications on the BCN Advantage HMO-POS Comprehensive Formulary that require prior authorization (PA) or step therapy (ST), and specifies clinical/administrative coverage criteria affecting prescribers and members.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyPrior authorization and step therapy criteria for formulary drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required documentation (diagnosis, prior therapy trials, and any specified test results) to request coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    387pages
    ~20+products listed
    1 YEARcommon auth duration
    cannot combine biologicsbiologic overlap exclusion
    LIFETIMEsome durations

    Coverage Criteria (Product-specific)

    Adbry (Atopic dermatitis) - Initial and reauthorization

    Covered when ALL of the following are met:

    Adbry initial coverage: Patient is at least 12 years of age with a diagnosis of moderate to severe atopic dermatitis AND trial and treatment failure of one of: high-potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil.age >=12 years

    Prior authorization required; reauthorization requires documentation of positive clinical response; for patients <100 kg who achieve positive response after 16 weeks dosage limited to 300 mg every 4 weeks unless clinical rationale provided.

    Adbry reauthorization: Documentation of positive clinical response to therapy is provided at time of reauthorization.

    Coverage duration 1 year; cannot be used in combination with another biologic/targeted DMARD indicated for the same condition.

    Selected prior therapy/combination requirements

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyPrior authorization and step therapy criteria for formulary drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required documentation (diagnosis, prior therapy trials, and any specified test results) to request coverage.
    SourceLink
    On This Page
    Coverage Criteria (Product-specific)Initial Therapy / Start-of-Care CriteriaReauthorization / Continuation CriteriaProvider Actions, Documentation & Denial RisksStep Therapy Rules & TablesCoding and Numeric ThresholdsDefinitions & TermsSite-of-Care & Billing DeterminationsBackground and Policy Basis

    Examples of prerequisite trial or combination requirements used across listed products:

    Breast cancer combination requirement: Coverage for advanced HR-positive, HER2-negative breast cancer requires combination use with exemestane and prior trial of letrozole or anastrozole.

    Example: everolimus + exemestane requirement (chunk 3).

    Methotrexate prerequisite (rheumatologic agents): Certain products require trial of methotrexate tablet or documented inability to use oral methotrexate prior to coverage.

    See product-specific entries (chunk 72).

    Topical steroid prerequisite (dermatologic agents): Some topical/dermatology products require trial of at least one generic topical steroid prior to coverage.1 topical steroid trial

    Example: calcipotriene entry (chunk 18).

    Prior targeted/biologic trials for rheumatologic indications: Many biologics require trials of specified alternative biologics/DMARDs (e.g., two listed agents for RA, PsA, psoriasis) before coverage is approved.2 of listed alternatives where specified

    Examples: Cimzia, Simponi, Taltz entries (chunks 22,146,160).

    Oncology combination/prior-line requirements: Several oncology agents require combination use with a specified agent or prior lines of systemic therapy per indication (e.g., trials of vemurafenib + cobimetinib for certain BRAF indications, combination with low-dose cytarabine for Daurismo in AML).

    See chunks 14 and 29 for examples.

    Cimzia — coverage with criteria

    Covered when ALL of the following are met:

    Cimzia general: Product used for an FDA-accepted indication AND not used in combination with another biologic or targeted DMARD indicated for the same condition.

    Coverage duration 1 year; reauthorization requires documentation of positive clinical response.

    RA prior therapies: Rheumatoid arthritis: diagnosis of moderately to severely active RA AND trial of two of: Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia.2 of list

    Per Cimzia RA criteria (chunk 22).

    Psoriatic arthritis prior therapies: Psoriatic arthritis: diagnosis of active PsA AND trial of two of: Cosentyx, Enbrel, adalimumab biosimilars, Rinvoq, Skyrizi, Wezlana/Yesintek, Xeljanz/XR, Orencia, Otezla.2 of list

    Per Cimzia PsA criteria (chunk 22).

    Cosentyx — coverage with criteria

    Covered when ALL of the following are met:

    Cosentyx general: Indication is medically accepted AND product is not used in combination with another biologic/targeted DMARD for the same condition.

    Coverage duration 1 year; reauthorization requires documentation of positive clinical response.

    Axial disease NSAID trial: For axial spondyloarthritis/ankylosing spondylitis/non-radiographic axial SpA or enthesitis-related arthritis, diagnosis plus trial of one NSAID (e.g., diclofenac, ibuprofen, meloxicam, naproxen).1 NSAID trial

    Per Cosentyx axial disease criteria (chunk 26).

    Dalfampridine — coverage with criteria

    Covered when ALL of the following are met:

    Dalfampridine general: Indication for multiple sclerosis with ambulatory impairment AND submission of baseline timed 25-foot walk (T25FW) prior to initiation.

    Excluded if patient is wheelchair bound or becomes wheelchair bound; reauthorization requires documentation of stability or improvement on T25FW (chunk 28).

    Dupixent — indication-specific criteria

    Covered when ALL of the following, indication-specific requirements are met:

    Dupixent general: Product used for an FDA-accepted indication AND not used in combination with another biologic/targeted DMARD for the same condition.

    Coverage duration 1 year; reauthorization requires documentation of positive clinical response.

    Atopic dermatitis (AD): Diagnosis of moderate to severe atopic dermatitis AND trial and treatment failure of one of: high-potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil.

    Applies for patients ≥2 years per product entry (chunks 32/33).

    Eosinophilic asthma (EA): Diagnosis of eosinophilic asthma with eosinophil count ≥150 cells/µL at initiation AND failure to maintain control after systemic corticosteroids or high-dose ICS plus trial of one additional controller (e.g., leukotriene modifier, LABA, or LAMA).eosinophils >=150

    Chunk 32/33

    COPD add-on maintenance: Uncontrolled moderate to severe COPD with eosinophils ≥300 cells/µL AND patient currently receiving and will continue LABA, LAMA, and an inhaled corticosteroid unless contraindicated.eosinophils >=300

    Chunk 33

    Copaxone / Glatiramer products

    Covered when ALL of the following are met:

    Glatiramer general: Use consistent with medically-accepted indications for glatiramer products.

    Coverage duration typically 1 year per group listing.

    Daurismo (glasdegib) — AML combination requirement

    Covered when ALL of the following are met:

    Daurismo (glasdegib): Newly diagnosed acute myeloid leukemia (AML) coverage requires combination use with low‑dose cytarabine.

    Per product criteria (chunk 29).

    Diacomit — anticonvulsant prerequisite

    Covered when ALL of the following are met:

    Diacomit general: Trial of two generic anticonvulsants documented AND for Dravet-associated seizures, combination use with clobazam is required.2 anticonvulsant trials

    Per Diacomit entry (chunk 30).

    L-glutamine — sickle cell criteria

    Covered when ALL of the following are met:

    L-glutamine general: Patient experienced ≥2 sickle cell–related vaso‑occlusive crises in the past 12 months AND trial of or intolerance to hydroxyurea documented.>=2 crises in 12 months

    Per L‑glutamine product entry (chunk 37).

    RA initial coverage — rheumatoid arthritis products with prerequisite therapy

    Covered when ALL of the following are met:

    RA initial coverage: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of at least one DMARD (e.g., methotrexate, leflunomide, sulfasalazine).

    Coverage duration commonly 1 year (chunk 36).

    JIA initial coverage

    Covered when ALL of the following are met:

    Polyarticular juvenile idiopathic arthritis (JIA): Diagnosis of active polyarticular JIA AND trial of leflunomide or methotrexate documented.

    Coverage duration 1 year (chunk 36).

    Eosinophilic asthma coverage

    Covered when ALL of the following are met:

    Eosinophilic asthma (EA): Diagnosis of eosinophilic asthma with eosinophil count ≥150 cells/µL at initiation AND failure to maintain control after systemic corticosteroids OR high‑dose inhaled corticosteroids plus trial of one additional controller (leukotriene modifier, LABA, or LAMA).eosinophils >=150/µL

    Reauthorization requires documentation of positive clinical response (chunks 44–45).

    EGPA coverage

    Covered when ALL of the following are met:

    EGPA coverage: Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) AND history or presence of asthma AND at least two typical EGPA features (e.g., histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, or ANCA positivity).

    Reauthorization requires documentation of positive clinical response (chunk 44).

    Cannabidiol (Epidiolex) coverage

    Covered when ALL of the following are met:

    Epidiolex (cannabidiol) indications: For Lennox‑Gastaut or TSC seizures: trial of two generic alternatives for seizures documented. For Dravet syndrome: trial of two of valproic acid, clobazam, or topiramate documented.

    Coverage duration 1 year (chunk 38).

    Topiramate coverage

    Covered when ALL of the following are met:

    Topiramate uses: For migraine prevention: trial of ≥2 generic alternatives for prevention OR inability to swallow tablets/capsules. For seizure disorder: trial of ≥2 generic anticonvulsants OR inability to swallow tablets/capsules.

    Coverage duration 1 year (chunk 39).

    Osteoporosis criteria

    Covered when ALL of the following are met:

    Osteoporosis criteria: Documentation of bone mineral density with T‑score ≤ -2.5.T-score ≤ -2.5

    Some products require trial of Jubbonti or Stoboclo and an oral bisphosphonate (see chunk 49).

    Gattex criteria

    Covered when ALL of the following are met:

    Gattex: Documentation that the patient has been dependent on parenteral support for ≥12 months.≥12 months

    Coverage duration 1 year (chunk 51).

    Gilotrif coverage

    Covered when ALL of the following are met:

    Gilotrif (afatinib): Use for metastatic NSCLC with non-resistant EGFR mutations detected by an FDA‑approved test OR for metastatic NSCLC progressing after platinum‑based chemotherapy as specified.

    Mutation testing required (chunk 53).

    GLP-1 agent coverage

    Covered when ALL of the following are met:

    GLP-1 agent coverage: Ongoing treatment for type 2 diabetes mellitus with submission of medical records confirming T2DM OR lab evidence (A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hr PG ≥200 mg/dL).A1c >=6.5% or FPG >=126 mg/dL or 2-hr PG >=200 mg/dL

    Excluded if used for weight‑loss only (chunk 54).

    T2DM indication requirements

    Covered when ALL of the following are met:

    T2DM-specific coverage requirements: Submission of medical records confirming diagnosis of type 2 diabetes mellitus OR lab evidence: A1c ≥6.5% OR fasting plasma glucose ≥126 mg/dL OR 2‑hour plasma glucose ≥200 mg/dL during OGTT.A1c >=6.5% or FPG >=126 mg/dL or 2-hr PG >=200 mg/dL

    Per GLP‑1/T2DM documentation requirements (chunk 54).

    Biologics — RA, JIA, AS, IBD coverage criteria

    Rheumatologic/autoimmune biologics — Covered when ALL of the following are met:

    General biologic rules: Indication consistent with product labeling AND medication is not used in combination with another biologic/targeted DMARD for the same condition; reauthorization requires documentation of positive clinical response.

    Applies across rheumatologic biologics (chunks 58,59).

    Indication-specific prior therapy requirements: RA: trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine). Polyarticular JIA: trial of methotrexate or leflunomide. AS: trial of an NSAID. IBD: diagnosis of moderately to severely active disease as specified per product.

    See individual product entries for required number/type of prior agents (chunks 58,59,36).

    Oncology agent coverage criteria

    Oncology/specialty targeted agents — Covered when ALL of the following are met:

    Ibrance specific: HR‑positive, HER2‑negative advanced/metastatic breast cancer requires combination use with an aromatase inhibitor as initial endocrine‑based therapy or fulvestrant after progression; other combination/prior‑therapy rules apply per indication.

    Chunk 60

    Inqovi specific: Coverage requires prior trial with azacitidine where indicated.

    Chunk 66

    APDS (Joenja) coverage criteria

    Covered when ALL of the following are met:

    Joenja (APDS): Diagnosis of APDS with associated PI3Kδ mutation AND documented variant in PIK3CD or PIK3R1 AND documented symptoms associated with APDS (e.g., nodal/extranodal lymphoproliferation, recurrent oto‑sino‑pulmonary infections, organ dysfunction).

    Cannot be used in combination with an immunosuppressive medication (chunk 71).

    Product-specific coverage criteria (selected examples)

    Product-specific examples — each entry summarizes the primary prerequisite or condition required for initial coverage:

    Methotrexate prerequisite (example): Coverage requires trial of methotrexate tablet or documented difficulty using oral methotrexate.

    Chunk 72

    Kevzara (sarilumab): RA: diagnosis of moderately to severely active RA AND trial of two listed agents (e.g., Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia); PMR: prior corticosteroid history and inadequate response; polyarticular JIA: trial of two listed agents.

    Chunk 74

    Kisqali (ribociclib): HR‑positive, HER2‑negative advanced/metastatic breast cancer requires combination with an aromatase inhibitor or fulvestrant per indication.

    Chunk 76

    Mekinist / BRAF‑MEK agents: BRAF V600E or V600K mutation required for specified indications; many BRAF/MEK agents require combination use with a companion BRAF inhibitor or trial of vemurafenib + cobimetinib as specified.BRAF V600E/V600K mutation

    Chunks 90,93,95

    Lenalidomide: For multiple myeloma: requires combination use with dexamethasone; other hematologic indications have specific prior‑therapy requirements (chunk 133).

    Chunk 133

    Mekinist coverage criteria

    Mekinist coverage — covered when ALL of the following are met:

    Mekinist general coverage: Indication consistent with labeling and BRAF V600E or V600K mutation detected by an FDA‑approved test.BRAF V600E/V600K mutation

    Coverage duration 1 year; liquid formulation covered only if patient unable to swallow tablets (chunks 90,93).

    Combination therapy requirement: For unresectable/metastatic melanoma, Mekinist monotherapy only for BRAF‑inhibitor treatment‑naive patients OR requires combination with dabrafenib; for other BRAF‑mutant indications (NSCLC, ATC, solid tumors, low‑grade glioma) coverage generally requires combination with dabrafenib or prior combination trial as specified.

    Chunks 90,93,94

    Mektovi coverage criteria

    Covered when ALL of the following are met:

    Mektovi (binimetinib): Coverage for unresectable or metastatic melanoma with BRAF V600E or V600K mutation requires trial of vemurafenib + cobimetinib and combination use with encorafenib per product labeling.

    Coverage duration 1 year (chunk 95).

    Nucala coverage criteria

    Nucala is covered when ANY of the indication-specific criteria below are met:

    Nucala indications: Indicated uses include eosinophilic asthma, EGPA, HES, CRSwNP, and add‑on maintenance COPD when respective indication‑specific criteria are satisfied.

    Reauthorization requires documentation of positive clinical response (chunks 104,106).

    Nucala — eosinophilic asthma: Diagnosis of eosinophilic asthma with eosinophil count ≥150 cells/µL at initiation AND failure to maintain adequate control after trial of systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of one additional controller (leukotriene modifier, LABA, or LAMA).eosinophil >=150 cells/µL

    Applies to adults and children ≥12 years (chunks 104,106).

    Nucala — EGPA: Diagnosis of EGPA AND at least two typical EGPA features as listed in policy (e.g., histopathology, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity).

    Chunk 104/106

    Nurtec criteria

    Covered when ALL of the following are met:

    Nurtec (rimegepant) — acute migraine: Patient has acute migraine AND trial of at least two generic triptans (e.g., sumatriptan and rizatriptan) documented unless triptan therapy is contraindicated or not tolerated.trial of >=2 triptans

    Initial coverage period and reauthorization per product entry (chunk 98).

    Nexletol/Nexlizet criteria

    Covered when ALL of the following are met:

    Nexletol / Nexlizet initiation: Diagnosis of hypercholesterolemia (including HeFH) or increased cardiovascular risk AND trial of one high‑intensity statin unless statin intolerance or contraindication documented.statin trial

    Examples and statin intolerance considerations provided in product entry (chunks 100–101).

    Acute migraine products - coverage conditions

    Covered when ALL of the following are met:

    Acute migraine product prerequisites: Patient has acute migraine AND documented trial of at least two generic triptans (unless contraindicated, not tolerated, or clinically inappropriate).trial of >=2 triptans

    Applies to listed acute migraine products (chunk 108).

    Posaconazole DR - prophylaxis and treatment coverage

    Covered when ALL of the following are met:

    Posaconazole DR — prophylaxis eligibility: Patient at high risk for invasive fungal infection (e.g., HSCT with GVHD, hematologic malignancy with prolonged neutropenia) AND documented trial of two of: fluconazole, itraconazole, or voriconazole.trial of 2 alternative azoles

    Coverage duration 6 months (chunk 122).

    Posaconazole DR — treatment eligibility: Used for treatment of invasive fungal infections caused by Aspergillus or Candida with documented trial of two alternative agents as specified.trial of 2 alternatives

    Chunk 122

    Opfolda - Pompe disease coverage

    Covered when ALL of the following are met:

    Opfolda (Pompe disease): Confirmation of decreased acid alpha‑glucosidase activity on serum assay AND genetic testing confirming a pathogenic GAA gene mutation AND symptomatic manifestations consistent with Pompe disease; no improvement on current ERT documented.diagnostic assay + genetic test

    Per Opfolda criteria (chunk 111).

    Orencia - autoimmune indications

    Covered when ALL of the following are met:

    Orencia (abatacept) — RA prerequisites: Diagnosis of moderately to severely active RA AND trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine); abatacept must not be used in combination with other immunosuppressives (e.g., JAK inhibitors, other biologic DMARDs).trial of >=1 DMARD

    Reauthorization requires documentation of positive clinical response and that abatacept is not combined with other immunosuppressives (chunk 113).

    Orencia — JIA prerequisites: Active polyarticular JIA AND trial of methotrexate or leflunomide documented.trial of 1 DMARD

    Chunk 113

    Orenitram - pulmonary arterial hypertension

    Covered when ALL of the following are met:

    Orenitram (PAH): Diagnosis of pulmonary arterial hypertension AND trial and failure or contraindication to sildenafil documented (titration kits also require trial/failure or contraindication to inhaled treprostinil and sildenafil).trial of sildenafil

    Chunk 114

    Praluent - lipid disorders (initiation and reauthorization)

    Covered when ALL of the following are met:

    Praluent initiation criteria: Indication: ASCVD, primary hyperlipidemia, HeFH, or HoFH as defined in policy AND trial of ≥12 weeks of high‑intensity statin (or documented statin intolerance) with LDL measured within last 120 days meeting LDL thresholds (≥55 mg/dL with ASCVD or >70 mg/dL without ASCVD) when on high‑intensity statin.LDL thresholds and statin trial

    Reauthorization requires continued statin if tolerated and documented LDL reduction; coverage duration 3 years (chunk 125).

    Jubbonti and Stoboclo - osteoporosis-related coverage

    Covered when ALL of the following are met:

    Jubbonti / Stoboclo (osteoporosis): Documentation of BMD T‑score ≤ -2.5 AND trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate (coverage provided if patient unable to receive both); subject to Part B vs Part D review.trial of bisphosphonate or inability to tolerate

    Coverage duration 3 years; explicit exclusion for hypocalcemia (chunk 127).

    Piqray - PIK3CA-mutated breast cancer

    Covered when ALL of the following are met:

    Piqray (alpelisib): Diagnosis of HR‑positive, HER2‑negative, PIK3CA‑mutated advanced or metastatic breast cancer with progression on or after an endocrine‑based regimen AND use in combination with fulvestrant.progression on endocrine therapy

    Per Piqray criteria (chunk 119).

    Otezla - psoriatic/psoriasis coverage

    Covered when ALL of the following are met:

    Otezla indications: Diagnosis of psoriatic arthritis, plaque psoriasis, or related indicated conditions AND product not used in combination with another biologic/targeted DMARD for the same condition.

    Reauthorization requires documentation of positive clinical response (chunk 116).

    General reauthorization/coverage durations

    General notes on authorization and duration across products:

    Coverage durations commonly set to 1 year for many products; select products have alternate durations (e.g., 3 years for some lipid/osteoporosis entries, 6 months for posaconazole DR prophylaxis).duration per product

    See individual product entries for specific durations (chunk 118).

    Prevymis coverage

    Covered when ALL of the following are met:

    Prevymis (CMV prophylaxis): CMV prophylaxis in CMV‑seropositive allogeneic HSCT recipients or in high‑risk kidney transplant recipients (D+/R-) per product criteria.

    Coverage duration 1 year (chunk 126).

    Jubbonti / Stoboclo coverage

    Covered when ALL of the following are met:

    Jubbonti / Stoboclo initial criteria: Trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate; coverage provided if patient unable to be treated with both; subject to Part B vs Part D review.trial of bisphosphonate or inability to tolerate

    Coverage duration 3 years (chunk 127).

    Eltrombopag coverage

    Covered when ALL of the following are met:

    Eltrombopag indications & thresholds: Indication‑specific baseline platelet thresholds: ITP: baseline platelets <30,000/mcL; HCV‑associated thrombocytopenia: baseline platelets <75,000/mcL; severe aplastic anemia: baseline platelets <30,000/mcL. ITP requires trial of corticosteroids, IVIG, or splenectomy.platelet thresholds as listed

    Coverage duration 1 year (chunk 128).

    Lenalidomide coverage

    Covered when ALL of the following are met:

    Lenalidomide — multiple myeloma: Use in combination with dexamethasone for multiple myeloma per product labeling; other lymphoma and hematologic indications have specific combination/ prior‑therapy requirements.

    Prescribed by or in consultation with an oncologist/hematologist; coverage duration 1 year (chunk 133).

    Rezdiffra coverage and renewal

    Covered when ALL of the following are met:

    Rezdiffra initial coverage: Diagnosis of noncirrhotic NASH or MASH with advanced liver fibrosis (stage F2–F3) verified by FibroScan or other imaging‑based noninvasive assessment AND trial of semaglutide documented.F2–F3 fibrosis

    Renewal requires no progression to cirrhosis and specified evidence of improvement or stabilization (chunk 135).

    Rezurock coverage

    Covered when ALL of the following are met:

    Rezurock (chronic GVHD): Age ≥12 AND diagnosis of chronic graft‑versus‑host disease (chronic GVHD) AND trial and failure of at least two prior lines of systemic therapy documented.failure of ≥2 prior lines

    Coverage duration 1 year (chunk 136).

    Rinvoq coverage

    Covered when ALL of the following are met:

    Rinvoq / Rinvoq Lq general: Indication‑specific diagnostic criteria met AND prerequisite trials as specified (e.g., DMARDs, NSAIDs, TNF inhibitors where required). Reauthorization requires documentation of positive clinical response and product not used in combination with potent immunosuppressants or another biologic/targeted DMARD for same condition.

    Coverage duration 1 year; prerequisite Part D drug required where indicated (chunks 137–139).

    Rinvoq Lq pediatric JIA: Polyarticular JIA requires trial of methotrexate or leflunomide.

    Chunk 137–139

    Rivfloza coverage

    Covered when ALL of the following are met:

    Rivfloza (lumasiran): Diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by AGXT mutation genetic testing AND absence of prior kidney or liver transplant and not used in combination with OXLUMO.genetic confirmation of AGXT mutation

    Coverage duration 1 year (chunk 140).

    Rybrevant coverage

    Covered when ANY of the following indication‑specific conditions are met:

    Rybrevant indications: NSCLC with EGFR exon 20 insertion: disease progression on or after platinum‑based chemotherapy; other EGFR mutation contexts require combination or prior‑therapy per indication.

    Coverage duration 1 year (chunk 142).

    Rydapt coverage

    Covered when ALL of the following are met:

    Rydapt (midostaurin): Newly diagnosed FLT3‑mutation positive AML: use in combination with standard cytarabine + daunorubicin induction and cytarabine consolidation per product labeling.

    Coverage duration 1 year (chunk 143).

    Tolvaptan coverage

    Covered when ALL of the following are met:

    Tolvaptan: Documentation that the patient does not have underlying liver disease AND trial of at least two of: furosemide, demeclocycline, or fluid restriction.

    Coverage duration 1 month; prerequisite Part D drug required (chunk 144).

    Secuado coverage

    Covered when ALL of the following are met:

    Secuado (schizophrenia): Trial of asenapine tablet (sublingual) documented OR documented inability to use oral/ODT formulations AND indication supports use.

    Coverage duration listed as lifetime (chunk 145).

    Initial criteria (example product)

    Example product initial-coverage pattern (illustrative entry from document):

    Example initial criteria: Documentation that the patient does not have underlying liver disease AND trial of at least two of: furosemide, demeclocycline, or fluid restriction; coverage duration per product entry.

    From illustrative example in chunk 144.

    Simponi — indication-specific criteria

    Simponi covered when ALL indication‑specific prerequisites are met:

    Simponi — RA: Diagnosis of moderately to severely active RA AND trial of two of: Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia AND combination use with methotrexate where specified.2 trials

    Reauthorization requires documentation of positive clinical response (chunks 146–147).

    Simponi — PsA/AS/UC: For PsA/AS/UC: diagnosis of indicated disease AND trial of two listed alternative agents as specified per indication.2 trials

    Chunks 146–147

    Stivarga — colorectal cancer

    Stivarga is covered when ALL of the following are met:

    Stivarga — colorectal cancer prerequisites: Previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy AND an anti‑VEGF therapy AND if RAS wild‑type, an anti‑EGFR therapy.

    Per Stivarga CRC criteria (chunk 153).

    Tagrisso — indication-specific coverage

    Tagrisso is covered when ANY of the indication‑specific conditions below are met:

    Adjuvant therapy: EGFR exon 19 deletion or exon 21 L858R mutation‑positive NSCLC as adjuvant therapy after tumor resection.

    Chunk 159

    First‑line metastatic: First‑line treatment for metastatic disease with specified EGFR mutations.

    Chunk 159

    T790M mutation: EGFR T790M mutation‑positive NSCLC after progression on an EGFR TKI.

    Chunk 159

    Talzenna / Erlotinib coverage highlights

    Covered when ALL of the following are met:

    Talzenna (mCRPC): Use in metastatic castration‑resistant prostate cancer requires combination with enzalutamide per product labeling.

    Coverage duration one year (chunk 162).

    Erlotinib (NSCLC): Concurrent treatment with first‑line, maintenance, or second‑or‑greater line treatment after progression following at least one prior chemotherapy regimen is required; for pancreatic cancer requires combination with gemcitabine.

    Prescriber should be an oncologist; coverage duration 1 year (chunk 162).

    Actemra

    Actemra coverage requires ALL of the following:

    Actemra — RA criteria: Diagnosis of moderately to severely active RA AND trial of two of: Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia; reauthorization requires documentation of positive clinical response.2 trials

    Chunk 169

    Tetrabenazine

    Tetrabenazine coverage constraints and exclusions — ALL must be met:

    Tetrabenazine exclusions: Patient must not have hepatic function impairment; must not be actively suicidal or have untreated/inadequately treated depression; must not be taking MAOI or reserpine.

    CYP2D6 genotype documentation required for doses >50 mg/day (chunk 166).

    Verquvo — Heart failure initial therapy

    Covered when ALL of the following are met:

    Verquvo (heart failure) entry criteria: Diagnosis of chronic heart failure NYHA class II‑IV AND LVEF <45% AND either prior hospitalization for heart failure within prior 6 months OR outpatient IV diuretic treatment within prior 3 months.LVEF <45%

    Must be taken with at least two guideline heart failure therapies unless contraindicated; coverage duration 1 year (chunk 180).

    Background therapy requirement: Concurrent use of at least two of: (1) metoprolol succinate/carvedilol/bisoprolol; (2) ACE inhibitor/ARB/ARNI; (3) an SGLT2 inhibitor approved for HF; (4) a mineralocorticoid receptor antagonist unless contraindicated.

    Chunk 180

    Verzenio covered indications

    Verzenio covered indications — ANY of the following:

    Adjuvant high‑risk EBC: Adjuvant treatment of adult HR‑positive, HER2‑negative, node‑positive early breast cancer at high risk of recurrence when used with tamoxifen or an aromatase inhibitor.

    Coverage duration 1 year (chunk 182).

    Advanced/metastatic initial endocrine‑based therapy: HR‑positive, HER2‑negative advanced/metastatic breast cancer when combined with an aromatase inhibitor as initial endocrine‑based therapy.

    Chunk 182

    Post‑endocrine progression: Advanced/metastatic breast cancer with progression following endocrine therapy requires combination with fulvestrant.

    Chunk 182

    Monotherapy metastatic indication: Monotherapy for disease progression requires prior endocrine and chemotherapy in the metastatic setting; prerequisite Part D drug required where specified.

    Chunk 182

    H. pylori treatment criteria

    H. pylori treatment — covered when ALL of the following are met:

    H. pylori diagnosis and prior regimen: Confirmed diagnosis of Helicobacter pylori infection AND trial of a guideline‑recommended first‑line regimen (clarithromycin triple therapy or bismuth quadruple therapy) documented prior to use of the product.

    Coverage duration 1 year (chunk 184).

    Voydeya coverage criteria

    Voydeya is covered when ALL of the following are met:

    Voydeya (EVH with PNH): Clinically significant extravascular hemolysis due to PNH AND laboratory thresholds of hemoglobin ≤9.5 g/dL AND absolute reticulocyte count ≥120 × 10^9/L AND concomitant use with Soliris or Ultomiris only.Hgb ≤9.5 g/dL; retic ≥120 ×10^9/L

    Coverage duration 1 year (chunk 187).

    Xolair covered indications and criteria

    Xolair covered indications — ANY of the following when prerequisites met:

    Allergic asthma: Uncontrolled moderate to severe allergic asthma with positive skin test or in‑vitro reactivity to a perennial aeroallergen AND IgE level in the specified age‑appropriate range AND failure to maintain control after systemic corticosteroids or high‑dose ICS plus trial of an additional controller.IgE ranges per age

    Reauthorization requires documentation of positive clinical response (chunks 197–198).

    Chronic spontaneous urticaria (CSU): Diagnosis of CSU with symptoms despite H1 antihistamine treatment AND trial of at least one second‑generation antihistamine documented.

    Chunk 197/198

    CRSwNP: Diagnosis of chronic rhinosinusitis with nasal polyposis and recurring symptoms despite prior intranasal corticosteroids (e.g., fluticasone, mometasone).

    Chunks 197–198

    Xermelo coverage criteria

    Covered when ALL of the following are met:

    Xermelo (carcinoid syndrome diarrhea): Trial of somatostatin analog therapy (e.g., octreotide, lanreotide) documented prior to coverage.

    Chunk 196

    Oncology agent coverage criteria (prior‑line requirements)

    Oncology prior‑line / line‑of‑therapy requirements (examples):

    Xpovio and related oncology agents: Coverage for multiple myeloma or relapsed/refractory indications requires documented failure of specified prior therapies or documented number of prior therapy lines/classes as listed for the product.document prior lines/classes

    See chunk 200 for examples.

    Zepzelca (SCLC): Metastatic small cell lung cancer requires disease progression on or after platinum‑based chemotherapy; maintenance extensive‑stage SCLC requires combination with atezolizumab and confirmation of no progression after first‑line induction therapy.

    Chunk 203

    Product-specific prerequisite trials

    Product‑specific prerequisite trials required for initial coverage (selected entries):

    Abilify Asimtufii / Maintena: Requires trial of oral aripiprazole prior to coverage; coverage duration typically lifetime.trial of oral aripiprazole

    Chunks 212–214.

    Oxcarbazepine ER TB24: Requires trial or intolerance to at least 2 generic anticonvulsants prior to coverage; coverage duration lifetime.2 trials

    Chunk 216/217.

    Invega Sustenna / Trinza / Perseris / Rasuvo etc.: Requires trial of specified oral or injectable alternatives (e.g., oral paliperidone or oral risperidone for Invega products; trial of generic methotrexate injection for Rasuvo; trial of oral risperidone for Perseris).trial of specified alternative

    Chunks 235,237,239,243.

    Rhopressa / Rocklatan: Requires trial of a generic formulary ophthalmic glaucoma medication or Lumigan prior to coverage.trial of ophthalmic glaucoma med

    Chunks 241,245.

    Rytary: Requires trial of generic oral extended‑release carbidopa/levodopa prior to coverage.trial of ER carbidopa/levodopa

    Chunk 249.

    Farxiga / Jardiance: Farxiga requires trial of generic dapagliflozin; Jardiance requires trial of generic dapagliflozin except when used to reduce cardiovascular death in adults with T2DM and established CVD (that use is exempt from step therapy).trial of dapagliflozin unless exempt

    Chunk 251.

    Febuxostat: Requires trial of or documented contraindication to allopurinol prior to coverage; coverage duration lifetime.trial or contraindication to allopurinol

    Chunk 253.

    Product-specific initial coverage criteria — prerequisite trials and step therapy

    Selected initial‑therapy step requirements (examples):

    Oxcarbazepine ER step: Requires trial or intolerance to at least two generic anticonvulsants prior to approval.2 trials

    Chunk 217.

    Antidepressant products step: Requires trial of at least two specified generic antidepressants prior to approval for referenced products.2 trials

    Chunk 219.

    Antipsychotic products step: Requires trial of at least one listed generic antipsychotic prior to approval for long‑acting injectable antipsychotics.1 trial

    Chunk 221.

    Invega Hafyera step: Requires prior use of once‑monthly paliperidone palmitate ER injectable for ≥4 months OR every‑three‑month paliperidone palmitate ER injectable for at least one 3‑month cycle prior to coverage.specified duration

    Chunk 231.

    SGLT2 step for Farxiga/Jardiance: Generic dapagliflozin must be tried before Farxiga or Jardiance except Jardiance when used to reduce risk of cardiovascular death in qualifying adults (exempt).trial of dapagliflozin unless exempt

    Chunk 251.

    General reauthorization/continuation rules

    Reauthorization/continuation requirements — covered when ALL of the following are met:

    Adbry reauthorization: Documentation of positive clinical response to therapy is provided.

    Chunk 2

    Dalfampridine reauthorization: Documentation of stability or improvement on timed 25‑foot walk (T25FW) compared with baseline documented.

    Chunk 28

    Biologics reauthorization: Documentation of positive clinical response to therapy for specified biologics (e.g., Cimzia, Enbrel, Simponi, Nucala, Orencia, Rinvoq) at reauthorization.

    Chunks 23,36,147,152

    Praluent continuation: Patient continues other lipid‑lowering therapy (unless intolerant) and has documented LDL reduction while on Praluent for reauthorization.documented LDL reduction

    Chunk 125

    No CPT/HCPCS/ICD-10 codes in this sectionmixed
    No codes listed

    Adbry (dupilumab) is not eligible for coverage when prescribed in combination with another biologic or targeted DMARD indicated for the same condition. This combination exclusion is explicit in the product-specific criteria and applies to initial and continuation authorizations for Adbry. Documentation of prior therapies and reauthorization requirements remain applicable when Adbry is used as a single biologic agent.

    Budesonide extended release is not covered for maintenance of remission in ulcerative colitis. The policy explicitly excludes this use and limits coverage to the product’s indicated, non-maintenance scenarios as specified in the formulary entry.

    Tadalafil is contraindicated for concomitant use with nitrate therapy; the policy states coverage is not provided when the patient is receiving nitrate therapy. Confirm active medication lists for nitrates before approving tadalafil.

    Dalfampridine is excluded for patients who are wheelchair bound or who become wheelchair bound. A baseline Timed 25-Foot Walk (T25FW) must be submitted prior to initiation, and reauthorization requires documentation of stability or improvement on the T25FW.

    For biologic therapies and other targeted DMARDs across multiple product entries, the policy consistently disallows combination use of one agent with another biologic or targeted DMARD indicated for the same condition. Requests that propose concurrent use of two such agents for the same diagnosis are excluded and may be denied.

    Coverage of Diacomit for seizures associated with Dravet syndrome requires concomitant use with clobazam. The policy specifies that Diacomit is not sufficient as monotherapy for Dravet-related seizures and requires that clobazam be used in combination.

    Initial Therapy / Start-of-Care Criteria

    ProductStep requirement
    Auvelity requires a trial of bupropion and one other generic formulary antidepressant prior to coverage for major depressive disorder (step therapy).
    Step therapy applies: prerequisite Part D drug required as listed in product entry.
    ProductStep requirement
    Requires prior trial of at least one generic topical steroid before coverage.
    Example product / classStep requirement (summary)
    Requires trials of specified alternative biologics/DMARDs per indication (e.g., trial of two listed alternatives for RA, PsA, plaque psoriasis, AS) prior to coverage; cannot be used in combination with another biologic/targeted DMARD for same condition.
    Many biologics require prior trials of specified alternative biologics or conventional therapies (often two listed alternatives) before coverage; combination use with another biologic/targeted DMARD for the same condition is not allowed.
    Product / indicationStep requirement
    For migraine prevention: trial of at least 2 generic alternatives for migraine prevention (or inability to swallow tablets/capsules). For seizure disorder: trial of at least 2 generic anticonvulsants (or inability to swallow tablets/capsules).
    Coverage requires trial of 2 generic anticonvulsant alternatives; for Dravet specifically trial of 2 of valproic acid, clobazam, or topiramate.
    Acute migraine agents require trial of at least two generic triptans (e.g., sumatriptan, rizatriptan) prior to coverage unless contraindicated or not tolerated.
    ProductStep requirement
    Requires trials of Jubbonti or Stoboclo AND an oral bisphosphonate (or IV bisphosphonate if intolerant) prior to coverage; documentation of BMD T-score ≤ -2.5 required.

    Reauthorization / Continuation Criteria

    Provider Actions, Documentation & Denial Risks

    Prior Authorization

    Prior authorization required for listed drugs

    Many formulary drugs listed in this section require prior authorization (PA); clinical and/or administrative criteria must be met before coverage is provided. Submit PA requests and supporting records that document the diagnosis, age, prior therapy trials, and any required test results per the product-specific criteria.

    • PA applies to numerous listed products; check individual product entries for prerequisites and exclusions.
    • Unless otherwise noted, authorization durations are commonly 1 year for covered products.
    Documentation Required

    Test documentation required when specified

    For some products the PA request must include specific diagnostic test documentation (example: documentation that the member passed the Bronchitol tolerance test when required). Provide the exact test results or lab reports cited in the product criteria.

    • Attach relevant laboratory or diagnostic test reports when specified by the product criteria.
    • Failure to include required test documentation may delay or prevent approval.
    Prior Authorization

    Prior authorization and authorization duration

    A prior authorization is required for most listed specialty agents; unless a different duration is specified in the product entry, approvals are typically issued for one year.

    • Check the product entry for any exceptions to the standard one‑year authorization duration.
    • If a shorter duration is specified (e.g., Tolvaptan = 1 month), follow the product-specific timeframe.
    Prior Authorization

    Cimzia — PA requires prior biologic/DMARD trials and reauthorization response

    Cimzia (certolizumab pegol) requires prior authorization and, for many indications, trials of specified alternative biologics/DMARDs before approval; reauthorization requires documentation of positive clinical response.

    • For RA, PsA, plaque psoriasis and related indications, document trials of the listed alternative agents and that Cimzia is not being used in combination with another biologic/targeted DMARD.
    • Include clinical notes showing positive response for reauthorization.
    Note
    Documentation Required

    Reauthorization requires documentation of positive clinical response

    Reauthorization of many biologic and specialty products requires submission of medical records documenting a positive clinical response to the therapy (e.g., symptom improvement or objective test improvement).

    • Include clinician progress notes, objective measurements, or test results demonstrating benefit when requesting renewal.
    • Lack of documented positive clinical response may result in denial at reauthorization.
    Documentation Required

    Prior authorization requires submission of medical-record evidence

    PA requests must include supporting medical-record evidence that confirms the requested indication and any required laboratory or diagnostic data (for example, documentation of T2DM or A1c values when required for GLP‑1 coverage).

    • Attach chart notes, lab reports (A1c, FPG, OGTT), imaging, genetic test results, or procedure reports as specified by the product criteria.
    • Incomplete or missing medical-record evidence may lead to denial or request for more information.
    Prior Authorization

    Prior trials required for rheumatologic/autoimmune indications

    For rheumatologic and other autoimmune biologics, prior authorization commonly requires documented trials of specified conventional therapies (e.g., DMARDs for RA/JIA or an NSAID for AS) before biologic therapy is approved.

    • Document prior DMARD trials (e.g., methotrexate, leflunomide, sulfasalazine) or NSAID use as applicable to the indication.
    • If a prior TNF inhibitor or other biologic is required, include therapy start/stop dates and reason for failure or intolerance.
    Note
    Note
    Note
    Note
    Prior Authorization

    Mektovi — PA requires combination with encorafenib and mutation confirmation

    Mektovi coverage requires prior authorization and must be used in combination with encorafenib for unresectable or metastatic melanoma with BRAF V600E/V600K mutations; document the BRAF mutation and prior trial(s) as specified.

    • Attach results of an FDA‑approved test showing the BRAF V600E or V600K mutation.
    • Include records showing the required trial of vemurafenib + cobimetinib where specified and that the combination with encorafenib will be used.
    Step Therapy

    Acute migraine step requirement — trial of two generic triptans

    Nurtec, Ubrelvy, and other acute migraine agents require prior trial of at least two generic triptans (e.g., sumatriptan, rizatriptan) unless triptan therapy is contraindicated, not tolerated, or clinically inappropriate; include trial documentation.

    • Document dates, dosages, and response/intolerance for the two triptan trials.
    • If triptan trials are contraindicated, provide clinical rationale.
    Note
    Prior Authorization

    Posaconazole DR — PA requires risk justification and trial of two alternative azoles

    Posaconazole DR prior authorization for prophylaxis/treatment requires documentation of the high‑risk condition and trials of two alternative azoles (fluconazole, itraconazole, or voriconazole) as specified.

    • Attach infectious disease or transplant documentation indicating HSCT with GVHD, prolonged neutropenia, or prior fungal infection requiring secondary prophylaxis.
    • Include records of the two alternative azole trials.
    Prior Authorization

    Praluent — PA requires statin trial and LDL documentation

    Praluent prior authorization requires documentation of ASCVD/primary hyperlipidemia/HeFH criteria, trial of high‑intensity statin at maximally tolerated dose (or documented statin intolerance), and LDL thresholds measured within the prior 120 days.

    • Provide LDL values while on high‑intensity statin (≥55 mg/dL with ASCVD or >70 mg/dL without ASCVD) and documentation of statin therapy or intolerance.
    • Include genetic confirmation or phenotype evidence for HoFH when applicable.
    Note
    Prior Authorization

    Prevymis — PA for CMV prophylaxis in defined transplant settings

    Prevymis PA is required for CMV prophylaxis in CMV‑seropositive HSCT recipients or high‑risk kidney transplant recipients (D+/R‑); include transplant serostatus and transplant type in the request.

    • Attach transplant records and CMV serostatus (donor/recipient) documentation.
    • Coverage duration noted as one year.
    Prior Authorization

    Jubbonti / Stoboclo — PA and bisphosphonate trial required

    Jubbonti and Stoboclo require prior authorization and Part B versus Part D review; approval requires trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate (documentation of intolerance or inability to receive both is acceptable).

    • Provide records documenting the oral bisphosphonate trial (or IV bisphosphonate if oral is intolerable) and any Part B/Part D status information.
    • Coverage duration for Jubbonti/Stoboclo is listed as 3 years.
    Prior Authorization

    Eltrombopag Olamine — baseline platelet thresholds and prior therapies required

    Eltrombopag Olamine PA requires baseline platelet counts and indication-specific thresholds: <30,000/mcL for persistent/chronic ITP, <75,000/mcL for HCV-associated thrombocytopenia, and <30,000/mcL for severe aplastic anemia; document prior therapies for ITP (corticosteroids, IVIG, or splenectomy).

    • Include baseline platelet count and records of prior ITP therapies or reasons for intolerance.
    • Coverage duration noted as 1 year.
    Prior Authorization

    Retevmo — genetic test confirmation and prior therapy documentation required

    Retevmo PA requires documented RET gene fusion/mutation detected by an FDA‑approved test for indicated uses; some indications also require prior systemic therapy or trial and failure of radioactive iodine when appropriate.

    • Attach the FDA‑approved test report confirming RET fusion/mutation.
    • For thyroid or other indications, include documentation of prior radioactive iodine or systemic therapy as specified.
    Prior Authorization

    Lenalidomide — PA requires oncologist involvement and prior therapy documentation

    Lenalidomide prior authorization requires prescribing by or in consultation with an oncologist/hematologist and documentation of indication‑specific prior therapy or combination use (e.g., use with dexamethasone in multiple myeloma).

    • Attach oncology consult notes and documentation of required combination regimens or prior therapy lines per the indication.
    • Coverage duration commonly one year.
    Prior Authorization

    Rezdiffra — semaglutide trial required and renewal documentation

    Rezdiffra (for NASH/MASH) requires prior authorization with a documented trial of semaglutide prior to approval; renewal requires no progression to cirrhosis and evidence of improvement or stabilization by imaging or noninvasive assessment.

    • Provide FibroScan or other imaging-based noninvasive assessment verifying F2–F3 fibrosis and documentation of a semaglutide trial.
    • For renewal, submit evidence of fibrosis improvement ≥1 stage or NASH resolution, or other documented clinical benefit.
    Prior Authorization

    Rezurock — PA requires failure of ≥2 prior systemic therapies

    Rezurock prior authorization for chronic GVHD (age ≥12) requires documented trial and failure of at least two prior lines of systemic therapy before approval.

    • Provide prior systemic therapy records including agents, durations, and reason for failure or intolerance.
    • Coverage duration listed as one year.
    Prior Authorization

    Rinvoq — PA requires prerequisite trials and reauthorization response

    Rinvoq (including Rinvoq Lq) prior authorization requires indication‑specific diagnostic criteria and prerequisite trials (e.g., DMARDs, NSAIDs, TNF inhibitors where specified); reauthorization requires documentation of positive clinical response and avoidance of prohibited combinations (potent immunosuppressants or another biologic for same condition).

    • Include records of prior conventional therapy trials and clinical response measures when requesting renewal.
    • Do not combine Rinvoq with potent immunosuppressants (azathioprine, cyclosporine) or another biologic/targeted DMARD—document current/concurrent therapies.
    Prior Authorization

    Rivfloza — genetic confirmation required; transplant and combination exclusions

    Rivfloza prior authorization requires genetic confirmation of primary hyperoxaluria type 1 (AGXT mutation); coverage is not provided for patients with a history of kidney or liver transplant or for combination use with OXLUMO.

    • Attach genetic testing confirming AGXT mutation.
    • Do not request coverage for patients with prior kidney or liver transplant or for concurrent OXLUMO; such requests will be excluded.
    Prior Authorization

    Rybrevant — prior platinum chemotherapy and mutation documentation required

    Rybrevant PA requires disease progression on platinum‑based chemotherapy for NSCLC with EGFR exon 20 insertions; other EGFR mutation contexts require the specified combination chemotherapy or prior EGFR TKI per indication.

    • Provide documentation of platinum‑based chemotherapy and disease progression for the EGFR exon 20 indication.
    • Include molecular testing for EGFR exon 20 insertion where applicable.
    Prior Authorization

    Rydapt — PA requires combination with standard induction/consolidation

    Rydapt prior authorization for newly diagnosed FLT3‑mutant AML requires combination with standard cytarabine and daunorubicin induction and cytarabine consolidation; include treatment plan documentation showing combination use.

    • Attach oncology treatment records confirming induction and consolidation regimens.
    • Coverage duration typically one year.
    Prior Authorization

    Tolvaptan — liver disease exclusion and prerequisite therapies required

    Tolvaptan PA requires documentation that the patient does not have underlying liver disease and a trial of at least two of: furosemide, demeclocycline, or fluid restriction; coverage duration is 1 month.

    • Provide liver evaluation/lab evidence ruling out underlying liver disease and records of trials of the specified alternatives.
    • Note the limited 1‑month authorization duration for initial coverage.
    Prior Authorization

    Secuado — PA requires trial of asenapine sublingual or documentation of inability to use oral/ODT

    Secuado for schizophrenia requires prior authorization and documentation of trial of sublingual asenapine or a note documenting inability to use oral/ODT formulations; coverage duration is listed as lifetime.

    • Submit records documenting the asenapine sublingual trial or documentation of swallowing/ODT intolerance.
    • Coverage duration is lifetime when criteria are met.
    Note
    Prior Authorization

    Scemblix — PA with one‑year duration (no prerequisite Part D drug)

    Scemblix requires prior authorization with a one‑year coverage duration; no prerequisite Part D drug is required for initiation.

    • Include diagnosis and prescriber details per the product entry when requesting PA.
    • Reauthorization follows the standard requirement for documentation of clinical response if listed.
    Prior Authorization

    Simponi — PA with two‑agent prior‑trial requirement and reauthorization response

    Simponi requires prior authorization (1 year); for many indications approval requires trials of two listed alternative agents and reauthorization requires documentation of positive clinical response.

    • For RA, PsA, AS and UC, provide documentation of the two required alternative agent trials as listed in the product criteria.
    • Include reauthorization evidence of clinical improvement for continued coverage.
    Prior Authorization

    Skyrizi / Sohonos — PA, combination exclusions, and Sohonos genetic confirmation

    Skyrizi and Sohonos require prior authorization with a 1‑year duration; Skyrizi cannot be used in combination with another biologic/targeted DMARD for the same condition and reauthorization requires documentation of positive clinical response; Sohonos for FOP requires genetic confirmation of an ACVR1 mutation.

    • For Skyrizi, include prior‑therapy trials per indication and confirm no concurrent biologic/targeted DMARD use.
    • For Sohonos, attach genetic test confirming ACVR1 mutation and documentation of clinical indication.
    Note
    Prior Authorization

    Stivarga — PA requires specified prior oncology therapies

    Stivarga prior authorization (one year) requires documentation of prior therapies for CRC, GIST, and HCC as specified (e.g., prior fluoropyrimidine-, oxaliplatin-, irinotecan‑based chemo and anti‑VEGF/anti‑EGFR where applicable).

    • Attach records showing the required prior chemotherapy regimens and targeted therapy trials before requesting Stivarga.
    • Coverage duration noted as one year.
    Prior Authorization

    Sunosi — trial of armodafinil required before approval

    Sunosi prior authorization requires a documented trial of armodafinil prior to coverage.

    • Provide clinical documentation of armodafinil trial and reason for failure or intolerance if Sunosi is requested.
    • Coverage duration listed as one year.
    Prior Authorization

    Tafinlar — PA requires prior trials/combination and liquid‑form rationale

    Tafinlar (including liquid) requires prior authorization (1 year) and, for many BRAF‑mutant indications, trial of vemurafenib + cobimetinib or combination use with trametinib as specified; liquid formulation is covered only if patient cannot swallow capsules.

    • Include mutation testing, prior therapy trials, and documentation that the capsule formulation cannot be used when requesting liquid.
    • Ensure combination therapy documentation is attached when required.
    Prior Authorization

    Tagrisso — PA requires EGFR mutation documentation and prior therapy per indication

    Tagrisso prior authorization (1 year) requires documentation of the specific EGFR mutation for the indicated NSCLC use (exon 19 deletion or exon 21 L858R, or T790M where applicable) and prior therapy details per indication.

    • Attach molecular testing reports confirming the EGFR mutation and records documenting prior EGFR TKI exposure or platinum‑based therapy where required.
    • Follow the indication‑specific prior‑therapy rules in the product entry.
    Prior Authorization

    Talzenna — PA requires combination with enzalutamide

    Talzenna for mCRPC requires use in combination with enzalutamide; document concomitant therapy per the product criteria.

    • Provide oncology treatment plan showing combination use with enzalutamide.
    • Coverage duration is one year.
    Prior Authorization

    Erlotinib — PA requires line‑of‑therapy and combination documentation

    Erlotinib prior authorization for NSCLC requires concurrent treatment sequencing per line of therapy and, for pancreatic cancer, use in combination with gemcitabine; prescriber should be an oncologist.

    • Include documentation of line of therapy and concurrent chemotherapy (gemcitabine) where applicable.
    • Ensure the prescriber is an oncologist or consultation is documented.

    Step Therapy Rules & Tables

    Example productsStep requirement
    Requires trial of one high-intensity statin unless statin intolerance or contraindication is documented prior to coverage.
    Requires trial of at least two generic triptans prior to coverage unless contraindicated or not tolerated.
    Requires trial of two generic anticonvulsant alternatives prior to coverage.
    Product / classRequirement
    Trial of at least two generic triptans (e.g., sumatriptan and rizatriptan) required prior to coverage unless contraindicated, not tolerated, or clinically inappropriate.
    ProductStep requirement
    Requires trial and failure or contraindication to sildenafil prior to coverage; titration kits require trial/failure or contraindication to inhaled treprostinil and sildenafil.
    ProductsStep requirement
    Require trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate prior to coverage; coverage also provided if unable to be treated with both; BMD documentation (T-score ≤ -2.5) required.
    ProductStep requirement
    Requires documentation of NASH/MASH with advanced liver fibrosis (F2–F3) and a prior trial of semaglutide before approval; renewal criteria specified.
    ProductStep requirement
    Coverage requires a trial of Betaseron prior to Rebif.
    ProductStep requirement
    Requires trial and failure of at least two prior lines of systemic therapy for chronic GVHD (age ≥12) prior to coverage.
    ContextSummary step requirement
    Multiple products require trials of specified alternative biologics or targeted agents (often two) prior to coverage; combination use with another biologic/targeted DMARD for the same condition is disallowed.
    ProductStep requirement (RA/JIA examples)
    For RA: requires trial of two of Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia; for polyarticular JIA similar multi-agent trial requirement; reauthorization requires documentation of positive clinical response.
    ProductStep requirement
    Requires trials of Jubbonti or Stoboclo and an oral bisphosphonate (or IV bisphosphonate if intolerant) before coverage; BMD documentation required (T-score ≤ -2.5).
    Product / contextRequirement
    Must be used in patients with chronic heart failure NYHA class II–IV with LVEF <45% plus either prior hospitalization for heart failure within prior 6 months or outpatient IV diuretic within prior 3 months; must be taken with at least two guideline-directed therapies unless contraindicated.
    Products (examples)Prerequisite Part D / step requirement
    Requires trial of generic dapagliflozin prior to Farxiga or Jardiance, except Jardiance when used to reduce cardiovascular death in qualifying adults (Jardiance exception).
    Requires background use of at least two guideline-directed heart failure therapies; prior therapy documentation required.
    ProductPrerequisite Part D example
    Subject to Part B versus Part D review; requires trial of an oral bisphosphonate or IV bisphosphonate if intolerant prior to coverage.
    Requires trial of semaglutide prior to approval for NASH/MASH; prerequisite Part D drug required.
    Product / groupStep requirement
    Requires trial of Betaseron prior to Rebif.
    Requires trial or intolerance to at least 2 generic anticonvulsants prior to coverage (lifetime duration).
    Requires trial of at least 2 specified generic antidepressants prior to coverage (lifetime duration).
    ProductStep requirement
    Requires trial or intolerance to at least 2 generic anticonvulsants prior to coverage; coverage duration lifetime.
    Requires trial of at least 2 listed generic antidepressants prior to coverage; coverage duration lifetime.
    Require trial of at least one listed generic antipsychotic prior to coverage; coverage duration lifetime.
    ProductStep requirement
    Requires prior trial of once-monthly paliperidone palmitate ER injectable for ≥4 months OR every-three-month paliperidone palmitate ER injectable for at least one 3-month cycle before coverage.
    Require trial of oral paliperidone or oral risperidone prior to coverage; coverage duration lifetime.
    Class / productStep requirement
    Require documented trial of at least 2 specified generic antidepressants prior to coverage.
    Require trial of at least one listed generic antipsychotic prior to coverage.
    Requires trial or intolerance to at least 2 generic anticonvulsants prior to coverage.
    Product / contextStep requirement
    Requires prior trial of Betaseron before Rebif (step therapy).
    Requires trials of specified alternative agents (e.g., Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia) depending on indication before coverage; reauthorization requires documentation of positive clinical response.
    Often require trial of specified conventional therapies (DMARDs, NSAIDs, TNF inhibitors) or specified alternative biologics prior to approval.
    ProductStep requirement / exception
    Requires prior use of specified paliperidone palmitate injectable regimens (see Invega Hafyera entry) before coverage.
    Requires trial of generic dapagliflozin before Farxiga or Jardiance; exception: Jardiance when used to reduce risk of cardiovascular death in adults with T2DM and established CVD is exempt from step therapy.
    Product / classStep requirement
    Require trial of generic dapagliflozin prior to Farxiga or Jardiance, except Jardiance for reduction of cardiovascular death in qualifying adults (no step therapy).
    Require trial of one high-intensity statin prior to coverage unless documented statin intolerance exists.

    Coding and Numeric Thresholds

    Products Affected - Oxcarbazepine ERNDC-like
    Oxcarbazepine Er TB24 300MGProduct listing from formulary
    Oxcarbazepine Er TB24 600MGProduct listing from formulary
    Products Affected - Antidepressant/Related Productsmixed
    Desvenlafaxine Er TB24 100MGProduct listing from formulary
    Desvenlafaxine Er TB24 50MGProduct listing from formulary
    ExxuaProduct listing from formulary
    Exxua Titration PackProduct listing from formulary
    TrintellixProduct listing from formulary
    Products Affected - Antipsychotic Productsmixed
    CaplytaProduct listing from formulary
    RexultiProduct listing from formulary
    Vraylar CAPSProduct listing from formulary
    Zyprexa RelprevvProduct listing from formulary
    Products Affected - Apidra Insulinmixed
    ApidraProduct listing from formulary
    Apidra SolostarProduct listing from formulary
    Products Affected - Aristadamixed
    AristadaProduct listing from formulary
    Products Affected - Aristada Initiomixed
    Aristada InitioProduct listing from formulary
    Products Affected - Insulin Suppliesmixed
    Alcohol Prep Pads PADS 70%Supply listing from formulary
    Curity Gauze Pads 2"x2" 12 PlySupply listing from formulary
    Products Affected - Invega Hafyeramixed
    Invega HafyeraProduct listing from formulary
    Products Affected - Invega Sustennamixed
    Invega SustennaProduct listing from formulary
    Products Affected - Invega Trinzamixed
    Invega TrinzaProduct listing from formulary
    Adbry — weight-based dosing note (patients <100 kg)
    Adbry weight‑based dosing after 16 weeksFor patients weighing <100 kg who achieve a positive clinical response after 16 weeks, dosage is limited to 300 mg every 4 weeks unless clinical rationale for alternate dosing is provided.
    Age restrictionAt least 12 years of age for covered indications.
    Combination exclusionCannot be used in combination with another biologic or targeted DMARD indicated for the same condition.
    Eosinophil count thresholds — COPD and eosinophilic asthma
    Eosinophil threshold for eosinophilic asthmaEosinophil count ≥150 cells/µL at initiation is required for eosinophilic asthma coverage.
    COPD add‑on maintenance thresholdEosinophil count ≥300 cells/µL (current or within past 12 months) required for add‑on maintenance COPD indication.
    Documentation requirementFailure to maintain control after systemic corticosteroids or high‑dose ICS plus trial of an additional controller is required in addition to eosinophil thresholds.
    Dupixent — weight minimum for EoE
    Dupixent minimum weight for EoEPatient must weigh at least 15 kilograms for the eosinophilic esophagitis (EoE) indication.
    EoE prerequisite therapiesCoverage for EoE requires prior trial of a proton pump inhibitor or topical (esophageal) corticosteroid as specified.
    Age considerationsEoE coverage language appears within the Dupixent indication set that includes pediatric age considerations (see policy).
    Eosinophil threshold — ≥150 cells/µL at initiation
    Eosinophil threshold at initiationEosinophil count ≥150 cells/µL at initiation is required for coverage of eosinophilic asthma and similar indications.
    Higher thresholds referencedSome COPD/add‑on indications reference eosinophil counts ≥300 cells/µL (or within past 12 months) for eligibility.
    Reauthorization expectationReauthorization generally requires documentation of positive clinical response to therapy in addition to initial eosinophil criteria.
    Bone mineral density threshold (T‑score ≤ -2.5)
    BMD (T‑score) thresholdBone mineral density T‑score ≤ -2.5 is required for coverage of specified osteoporosis-related products.
    Required trialCoverage often requires trial of specified agents (e.g., Jubbonti or Stoboclo and an oral bisphosphonate or IV bisphosphonate if intolerant).
    DocumentationDocumentation of BMD (T‑score ≤ -2.5) must be submitted to support the request.
    Diabetes diagnostic thresholds (A1c/FPG/2‑hr PG)
    Diabetes diagnostic thresholdsType 2 diabetes mellitus can be documented by A1c ≥ 6.5% OR fasting plasma glucose ≥ 126 mg/dL OR 2‑hour plasma glucose ≥ 200 mg/dL (OGTT).
    Medical record evidence acceptedSubmit medical records/chart notes confirming T2DM diagnosis or the laboratory values listed above for GLP‑1 agent coverage.
    Weight‑loss exclusionCoverage for listed GLP‑1 agents is excluded if used for weight loss only.
    A1c, FPG, 2‑hour PG thresholds for T2DM
    A1c, FPG, 2‑hour PG thresholds for T2DMA1c ≥ 6.5%; Fasting plasma glucose (FPG) ≥ 126 mg/dL; 2‑hour plasma glucose (PG) ≥ 200 mg/dL during OGTT — acceptable lab evidence for T2DM.
    Use for documentationThese thresholds are used to confirm diagnosis when submitting medical records for ongoing T2DM treatment coverage.
    Exclusion noteProducts listed may be excluded if used solely for weight‑loss purposes — document indication clearly.
    Eosinophil count — ≥150 cells/µL at initiation; ≥300 cells/µL referenced for COPD
    Eosinophil count at initiation (general)Eosinophil count ≥150 cells/µL at initiation is required for eosinophilic asthma coverage; COPD add‑on may reference ≥300 cells/µL within past 12 months.
    COPD referenceFor COPD add‑on maintenance, an eosinophil count ≥300 cells/µL (or ≥150 with other criteria) within the prior 12 months may be required.
    Higher‑severity indicationsOther eosinophilic disorders (e.g., HES) may require much higher eosinophil counts per product‑specific criteria.
    LDL thresholds for Praluent initiation while on high‑intensity statin
    LDL thresholds while on high‑intensity statinFor Praluent initiation: LDL ≥ 55 mg/dL with ASCVD OR LDL > 70 mg/dL without ASCVD, measured within the last 120 days, while on a high‑intensity statin.
    Statin therapy requirementPatient must have received ≥12 weeks of a high‑intensity statin or have documented statin intolerance (and have tried atorvastatin and rosuvastatin if intolerant).
    HoFH noteHoFH criteria separate: genetic confirmation or specific untreated/treated LDL thresholds (see HoFH entry).
    HoFH treated/untreated LDL thresholds
    HoFH LDL thresholds (untreated/treated)Homozygous familial hypercholesterolemia (HoFH) initiation: untreated LDL > 500 mg/dL OR treated LDL > 300 mg/dL (or genetic confirmation per policy).
    Genetic confirmation optionHoFH may be confirmed by genetic testing showing two relevant mutations in LDLR, APOB, PCSK9, LDLRAP1 or ARH as alternative evidence.
    Prerequisite/statin contextPraluent HoFH and HeFH criteria reference background lipid‑lowering therapy and prior statin use or intolerance.
    Baseline platelet count (ITP) — <30,000/mcL
    Baseline platelet count — ITPBaseline platelet count < 30,000/mcL is required for coverage of eltrombopag for persistent/chronic immune thrombocytopenia (ITP).
    ITP prerequisite therapiesITP coverage requires prior trial of corticosteroids, IVIG, or splenectomy as applicable.
    Coverage durationCoverage duration listed as 1 year for eltrombopag indications.
    Baseline platelet count (HCV‑associated thrombocytopenia) — <75,000/mcL
    Baseline platelet count — HCV‑associated thrombocytopeniaBaseline platelet count < 75,000/mcL is required for coverage of eltrombopag for thrombocytopenia associated with chronic hepatitis C.
    Indication distinctionDifferent platelet thresholds apply by indication (e.g., <30,000/mcL for ITP vs <75,000/mcL for HCV‑associated thrombocytopenia).
    DocumentationSubmit baseline platelet count to support the request and indication.
    Advanced liver fibrosis stage for Rezdiffra — F2 to F3
    Advanced liver fibrosis stageRezdiffra coverage requires advanced liver fibrosis stage F2 to F3 verified by FibroScan or other imaging‑based non‑invasive liver disease assessment.
    Prerequisite therapyInitial approval requires a trial of semaglutide prior to Rezdiffra for NASH/MASH.
    Renewal criteriaRenewal requires no progression to cirrhosis and evidence of resolution, ≥1‑stage fibrosis improvement, or stabilization/clinical benefit per imaging or biomarkers.
    Bone mineral density (T‑score) — ≤ -2.5 (duplicate)
    BMD (T‑score) thresholdBone mineral density T‑score ≤ -2.5 required for coverage of specified osteoporosis products (same threshold referenced in multiple entries).
    Required prior agentsCoverage often requires trial of Jubbonti or Stoboclo and an oral bisphosphonate (or IV bisphosphonate if intolerant).
    Documentation requirementSubmit BMD report showing T‑score ≤ -2.5 to support the request.
    Tetrabenazine genotype threshold — CYP2D6 required for >50 mg/day
    Tetrabenazine CYP2D6 genotype requirementDocumentation of the patient's CYP2D6 genotype is required for dosing above 50 mg per day.
    Safety exclusionsCoverage will not be provided for patients with hepatic impairment, active suicidality or untreated/inadequately treated depression, or concomitant MAOI or reserpine use.
    Coverage durationCoverage duration listed as 1 year for tetrabenazine in the policy excerpt.
    Left ventricular ejection fraction — <45% threshold
    LVEF threshold for heart failure productsLeft ventricular ejection fraction (LVEF) <45% is required for coverage of specified heart failure therapies (e.g., Verquvo).
    NYHA requirement contextCoverage also requires NYHA class II–IV and recent worsening criteria (hospitalization within 6 months or outpatient IV diuretic within 3 months).
    Background therapy requirementMust be taken in combination with at least two guideline‑directed therapies unless contraindicated or not tolerated.
    Hemoglobin threshold — ≤9.5 g/dL (EVH/PNH)
    Hemoglobin threshold for EVH/PNH criteriaHemoglobin ≤ 9.5 g/dL is required for coverage of therapies for extravascular hemolysis (EVH) with PNH (e.g., Voydeya).
    Concurrent requirementsCoverage also requires absolute reticulocyte count ≥ 120 × 10^9/L and combination use with Soliris or Ultomiris.
    Coverage durationAuthorization duration commonly listed as 1 year for this indication.
    Absolute reticulocyte count — ≥120 × 10^9/L (EVH/PNH)
    Absolute reticulocyte count thresholdAbsolute reticulocyte count ≥ 120 × 10^9/L is required (with Hgb ≤9.5 g/dL) for EVH/PNH coverage.
    Concomitant therapyCoverage requires combination use with Soliris or Ultomiris for EVH in PNH.
    DocumentationSubmit recent CBC/reticulocyte count to support the request.
    Left ventricular ejection fraction (LVEF) — <45% (duplicate)
    LVEF threshold (duplicate)Left ventricular ejection fraction (LVEF) <45% — repeated requirement for heart failure products (duplicate entry).
    NYHA class requirementNYHA class II–IV required in conjunction with LVEF <45% per product criteria.
    Recent worsening criteriaEither prior hospitalization for heart failure within 6 months OR outpatient IV diuretic within 3 months is required in addition to LVEF/NYHA.
    Insulin claim lookback — claim within last 180 days
    Insulin claim lookbackCoverage for listed insulin‑related supplies (e.g., alcohol prep pads, gauze) requires a claim for an insulin product within the last 180 days.
    Coverage durationCoverage duration for these supplies is listed as 1 year.
    DocumentationProvide a recent claim or medical record showing insulin use within the prior 180 days to support supply coverage.

    Definitions & Terms

    Prior authorization (PA) — definition
    Prior authorization (PA)A process where clinical and/or administrative criteria must be met before drug coverage is provided.
    PurposePA ensures appropriate and cost‑effective drug therapy per formulary criteria.
    ApplicationDrugs subject to PA are identified in the formulary with (PA); criteria must be met prior to coverage.
    Step therapy (ST) — definition
    Step therapy (ST)A program requiring prior treatment with one or more formulary drugs before coverage of the requested drug.
    ExamplesST is applied to select drugs (marked in formulary with (ST)) and may require trials of specified agents (see product entries).
    Denial riskClaims may be denied if step‑therapy requirements are not met or not documented.
    Eosinophilic asthma (EA) — definition with eosinophil threshold
    Eosinophilic asthma (EA) definitionEA is defined as eosinophilic asthma with an eosinophil count ≥150 cells/µL at initiation for coverage of certain biologics (e.g., Dupixent, Nucala).
    Additional criteriaCoverage for EA also requires failure to maintain control after systemic corticosteroids or high‑dose ICS plus a trial of an additional controller medication.
    ReauthorizationReauthorization requires documentation of positive clinical response to therapy.
    Timed 25‑Foot Walk (T25FW) — definition
    Timed 25‑Foot Walk (T25FW)A baseline and follow‑up functional test required for dalfampridine coverage in multiple sclerosis to document stability or improvement.
    Baseline requirementSubmission of a baseline T25FW test is required prior to initiation.
    ReauthorizationReauthorization requires documentation of stability or improvement on the T25FW test.
    EGPA — definition
    EGPA definitionEosinophilic granulomatosis with polyangiitis (EGPA) coverage requires diagnosis plus two typical EGPA features (e.g., histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, or ANCA positivity).
    Age/indication notesSpecific documentation requirements and reauthorization conditions apply per product (e.g., Nucala, Fasenra entries).
    ReauthorizationReauthorization requires documentation of positive clinical response to therapy.
    T2DM documentation lab thresholds — A1c/FPG/2‑hr PG
    T2DM lab thresholds (definition)Used as evidence of type 2 diabetes mellitus: A1c ≥ 6.5%; fasting plasma glucose ≥ 126 mg/dL; 2‑hour plasma glucose ≥ 200 mg/dL during OGTT.
    ApplicationThese lab values may be submitted as medical evidence when requesting coverage for GLP‑1 agents or other T2DM therapies.
    Medical record optionAlternatively, chart notes confirming a T2DM diagnosis may be submitted.
    BRAF V600E or V600K mutation — definition for targeted therapy
    BRAF V600E/V600K mutation definitionPresence of a BRAF V600E or V600K genomic mutation detected by an FDA‑approved test — required for coverage of specified targeted therapies (e.g., Mekinist, Mektovi).
    Combination requirementMany BRAF/MEK agents require combination use with a companion BRAF or MEK inhibitor per indication.
    Monotherapy exceptionMonotherapy may be authorized only in specific BRAF‑inhibitor–treatment‑naive melanoma scenarios as noted in product entries.
    EGPA — duplicate definition grouping
    EGPA (duplicate) — definitionEGPA requires diagnosis plus at least two typical clinical criteria as listed in the policy for biologic eligibility and documentation.
    Required documentationProduct‑specific entries (e.g., Nucala) enumerate the acceptable EGPA features and medical information required for PA.
    ReauthorizationReauthorization requires documentation of positive clinical response.
    HeFH — definition
    HeFH definitionHeterozygous familial hypercholesterolemia (HeFH) defined by genetic confirmation or phenotype (examples include untreated LDL >190 mg/dL plus family history/xanthoma before age 10).
    Praluent contextHeFH is one of the indications referenced for Praluent initiation and reauthorization with LDL/statin criteria.
    DocumentationGenetic or phenotypic evidence may be used to support HeFH diagnosis per policy guidance.
    FOP — genetic confirmation requirement
    FOP genetic confirmationFibrodysplasia ossificans progressiva (FOP) coverage requires genetic testing confirmation showing an ACVR1 mutation.
    Prior authorizationPA is required and coverage duration commonly set to 1 year for FOP therapies (see Sohonos entry).
    DocumentationProvide genetic testing results demonstrating the ACVR1 mutation to support the request.
    EGFR mutation‑positive NSCLC — definition
    EGFR mutation‑positive NSCLC definitionEGFR exon 19 deletion or exon 21 L858R mutation‑positive NSCLC (and T790M contexts) as detected by appropriate testing — required for Tagrisso coverage per indication.
    Indication contextsCoverage scenarios include adjuvant, first‑line metastatic, and progression‑after‑EGFR‑TKI contexts depending on mutation status.
    Prerequisite therapyCertain EGFR mutation contexts require prior EGFR TKI progression or platinum‑based chemotherapy as specified.
    NYHA class II–IV — definition
    NYHA class II–IV definitionNew York Heart Association (NYHA) class II–IV denotes moderate to severe heart failure symptoms and is required documentation for certain heart failure therapies.
    Associated requirementsNYHA II–IV is paired with LVEF <45% and recent worsening criteria (hospitalization/IV diuretic) for PA eligibility in HF products like Verquvo.
    DocumentationProvide clinical documentation of NYHA functional class in the medical record when requesting HF product coverage.
    Clinically significant EVH — definition
    Clinically significant EVH definitionClinically significant extravascular hemolysis (EVH) due to PNH is defined by hemoglobin ≤ 9.5 g/dL and absolute reticulocyte count ≥ 120 × 10^9/L for coverage decisions.
    Concomitant therapyTreatment for EVH with PNH typically requires combination use with complement inhibitors (e.g., Soliris or Ultomiris).
    Authorization durationPA duration commonly listed as 1 year for Voydeya/EVH indications.
    CSU prerequisite and CRSwNP prerequisite
    CSU prerequisiteCoverage for chronic spontaneous urticaria (CSU) requires a trial of at least one second‑generation antihistamine prior to biologic therapy.
    CRSwNP prerequisiteCoverage for chronic rhinosinusitis with nasal polyposis requires prior intranasal corticosteroid therapy and recurring symptoms despite that therapy.
    DocumentationDocument trials of listed prior therapies when submitting PA requests for CSU or CRSwNP indications.

    Site-of-Care & Billing Determinations

    Note

    Background and Policy Basis

    The formulary prior authorization and step-therapy criteria are developed from medical evidence and the Blues’ Pharmacy & Therapeutics Committee recommendations. Prior authorization is required for many listed drugs and, unless otherwise specified, authorizations are generally issued for 1 year. Clinical requirements commonly include specific diagnoses, prerequisite trials of alternative or generic therapies, lab or diagnostic test documentation, and restrictions on prohibited combinations (for example, biologic overlap and certain contraindicated combinations).